GE-RENEWABLE-ENERGY
GE Renewable Energy’s Grid Solutions business (NYSE-GE) has been awarded €2.2 million through the European Commission’s LIFE climate action program to help fund the development of a sulfur hexafluoride (SF6 )-free, 420 kiloVolt (kV) 63 kilo Amps (kA) gas-insulated substation (GIS) circuit-breaker.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200213005296/en/
The new circuit-breaker will rely on GE’s industry-leading “Green Gas for Grid”—or “g3” (pronounced “g- cubed”)—technology, resulting in the same high performance and compact size as a traditional SF6 -insulated circuit-breaker, but with a gas mass having more than a 99% reduced CO₂ equivalent value. Upon completion in 2022, the g3 circuit-breaker is expected to be the first SF6 -free 420 kV gas-insulated substation circuit-breaker in the world.
A circuit-breaker is protective equipment used to cut power in case of a problem on the grid. High-voltage 420-kV circuit-breakers are found at electrical substations on long-distance transmission networks.
Due to its strong insulating and arc-quenching properties, SF6 is widely used in substation equipment with the transmission industry accounting for approximately 80% of the world’s usage. Identified as the world’s most potent greenhouse gas by the 1997 Kyoto Protocol, SF6 is estimated to contribute 23,500 times more emissions than CO₂ if leaked and can remain in the atmosphere for up to 3,200 years.
“Our g3 technology is a game-changing alternative to SF6 for high-voltage equipment and is part of GE’s broader efforts to help the electric transmission and distribution industry reduce its greenhouse gas emissions,” said Vera Silva, Chief Technology Officer at GE’s Grid Solutions.
“Because 420 kV is the highest voltage level used in most European countries, a proven g3 –insulated 420 kV circuit-breaker will demonstrate that g3 technology can be applied to other high-voltage levels, as well as all other gas-insulated substation components, such as disconnectors, earthing switches, voltage transformers,” said Yannick Kieffel, Grid Solutions’ Materials and Eco Design Team Leader and Project Leader for the EU-funded g3 project.
Currently, GE offers the following g3 products: live tank circuit-breakers and gas-insulated substations up to 145 kV, gas-insulated lines up to 420 kV and instrument transformers up to 245 kV.
“This project is a great fit for our recent round of LIFE financial awards due to its potential impact on Europe’s transition to a more sustainable and low-carbon future,” said Angelo Salsi, LIFE Programme Head of Unit at the Executive Agency for Small and Medium-sized Enterprises (EASME). “The LIFE program is one of the most efficient and well known EU funding mechanisms that has supported nature, the environment and climate action for over 25 years. We look forward to the positive ripple effect this project will have across Europe over the next decade and beyond.”
For the full press release on the g3 EU-funded circuit-breaker project LIFE18 CCM/FR/001096 LIFE GRID , click here .
GE’s Grid Solutions
Grid Solutions, a GE Renewable Energy business, serves customers globally with over 17,000 employees in approximately 80 countries. Grid Solutions helps enable utilities and industry to effectively manage electricity from the point of generation to the point of consumption, helping to maximize the reliability, efficiency and resilience of the grid. https://www.gegridsolutions.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200213005296/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom